{{medical}}
{{Drugbox
| verifiedrevid = 443859600
| IUPAC_name = 1-hydrazinylphthalazine
| image = Hydralazine.svg
| alt = Skeletal formula of hydralazine
| width = 125
| image2 = Hydralazine-3D-balls.png
| alt2 = Ball-and-stick model of the hydralazine molecule

<!--Clinical data-->
| tradename =  Apresoline, BiDil, others
| Drugs.com = {{drugs.com|monograph|hydralazine-hydrochloride}}
| MedlinePlus = a682246
| licence_US = Hydralazine
| pregnancy_AU = C
| pregnancy_US = C
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = [[口服给药|口服给药]]、[[靜脈注射|靜脈注射]]
<!--Pharmacokinetic data-->
| bioavailability = 26–50%
| protein_bound = 85–90%
| metabolism = [[肝臟|肝臟]]
| elimination_half-life = 正常：2–8小時<br>腎損傷：7–16 小時
| excretion = [[尿|Urine]]
| onset             = 5-30 分鐘<ref name=AHFS2016/>
| duration_of_action = 2-6 小時<ref name=AHFS2016/>

<!--Identifiers-->
| IUPHAR_ligand = 7326
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 86-54-4
| ATC_prefix = C02
| ATC_suffix = DB02
| PubChem = 3637
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01275
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3511
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 26NAK24LS8
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08044
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 5775
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 276832

<!--Chemical data-->
| C=8 | H=8 | N=4
| molecular_weight = 160.176 g/mol
| smiles = n2nc(c1ccccc1c2)NN
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RPTUSVTUFVMDQK-UHFFFAOYSA-N
}}
<!-- Definition and medical uses -->
'''肼屈嗪'''（{{lang|en|Hydralazine}}），又名'''肼苯哒嗪'''，是一種治療[[高血壓|高血壓]]和[[心臟衰竭|心臟衰竭]]的藥物<ref name=AHFS2016>{{cite web|title=Hydralazine Hydrochloride|url=https://www.drugs.com/monograph/hydralazine-hydrochloride.html|publisher=The American Society of Health-System Pharmacists|accessdate=8 December 2016|archive-date=2016-12-21|archive-url=https://web.archive.org/web/20161221010517/https://www.drugs.com/monograph/hydralazine-hydrochloride.html|dead-url=no}}</ref>。適應症包含[[妊娠高血壓|妊娠高血壓]]以及{{tsl|en|hypertensive emergency|高血壓急症}}<ref name=WHO2008/>。目前已知[[黑人|黑人]]若併用[[硝酸异山梨酯|硝酸异山梨酯]]治療心臟衰竭效果特別顯著<ref name=AHFS2016/>。本品可由口服或[[靜脈注射|靜脈注射]]給藥<ref name=WHO2008>{{cite book|title=WHO Model Formulary 2008|date=2009|publisher=World Health Organization|isbn=9789241547659|page=280|url=http://apps.who.int/medicinedocs/documents/s16879e/s16879e.pdf|accessdate=8 December 2016|archive-date=2016-12-13|archive-url=https://web.archive.org/web/20161213060118/http://apps.who.int/medicinedocs/documents/s16879e/s16879e.pdf|dead-url=no}}</ref>。藥效通常會於15分鐘左右開始作用，並持續6小時左右<ref name=AHFS2016/>。

<!-- Side effects and mechanism -->
肼屈嗪屬於[[血管舒張|血管舒張劑]]<ref name=AHFS2016/>，常見副作用包含[[頭痛|頭痛]]和[[心跳过速|心跳过速]]<!-- <ref name=AHFS2016/> -->。[[冠狀動脈疾病|冠狀動脈疾病]]以及[[風溼熱|風溼性心臟病]]造成[[二尖瓣|二尖瓣]]缺損的患者不建議使用<ref name=AHFS2016/>。[[腎功能衰竭|腎功能衰竭]]患者建議減低藥量<ref name=WHO2008/>。

<!-- Society and culture -->
肼屈嗪由[[诺华公司|诺华公司]]的研究人員在開發抗瘧藥物時的意外產品<ref name=Wermuth>{{cite book|last1=Wermuth|first1=Camille Georges|title=The Practice of Medicinal Chemistry|publisher=Academic Press|isbn=9780080568775|page=12|url=https://books.google.com/books?id=Qmt1_DQkCpEC&pg=PA12|language=en}}</ref>，並於1949年獲得專利<ref>{{cite book|title=Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrés des recherches pharmaceutiques|date=2013|publisher=Birkhäuser|isbn=9783034870948|page=206|url=https://books.google.ca/books?id=i8LzBwAAQBAJ&pg=PA206|language=en|access-date=2017-05-31|archive-date=2016-12-20|archive-url=https://web.archive.org/web/20161220130333/https://books.google.ca/books?id=i8LzBwAAQBAJ&pg=PA206|dead-url=no}}</ref>。本品列名於[[世界卫生组织基本药物标准清单|世界卫生组织基本药物标准清单]]，為基礎公衛體系必備藥物之一<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|archive-date=2016-12-13|archive-url=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|dead-url=no}}</ref>。一個月劑量在[[发展中国家|发展中国家]]的批發價位於2.78至9.11美金之間<ref name=ERC2014>{{cite web|title=Hydralazine|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=HDZ25T&s_year=2014&year=2014&str=25%20mg&desc=Hydralazine&pack=new&frm=TAB-CAP&rte=PO&class_code2=12%2E3%2E&supplement=&class_name=%2812%2E3%2E%29Antihypertensive%20medicines%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=8 December 2016}}{{dead link|date=2018年1月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>，在美國同等劑量則需約50至100美金<ref name=Ric2015>{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|page=145}}</ref>。

==作用机制==

肼屈嗪的作用机制尚未完全阐明。可能的作用机制包括：
* 干扰[[第二信使|第二信使]][[三磷酸肌醇|三磷酸肌醇]]作用，限制平滑肌细胞[[肌浆网|肌浆网]]的[[钙|钙离子]]释放<ref name="Rand and Dale">Rang, Dale, Ritter and Flower. Pharmacology. 6th Ed, 2007.</ref>；
* 作为[[一氧化氮|一氧化氮]]供体<ref name="urlantihtn">{{cite web|url=http://faculty.swosu.edu/scott.long/phcl/antihtn.htm|title=antihtn|format=|work=|accessdate=2008-10-05|deadurl=yes|archiveurl=https://web.archive.org/web/20081201140202/http://faculty.swosu.edu/scott.long/phcl/antihtn.htm|archivedate=2008-12-01}}</ref>；
* 激活[[缺氧诱导激活因子|缺氧诱导激活因子]]<ref name="pmid15192023">{{cite journal en |author=Knowles HJ, Tian YM, Mole DR, Harris AL |title=Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases |journal=Circ. Res. |volume=95 |issue=2 |pages=162–9 |pmid=15192023 |doi=10.1161/01.RES.0000134924.89412.70 |url=http://circres.ahajournals.org/cgi/pmidlookup?view=long&pmid=15192023 |date=July 2004 |access-date=2009-05-22 |archive-url=https://archive.is/20130112154811/http://circres.ahajournals.org/cgi/pmidlookup?view=long&pmid=15192023 |archive-date=2013-01-12 |dead-url=yes }}</ref>。

==临床应用==
由于肼屈嗪能通过[[减压反射|减压反射]]引起[[心脏|心脏]][[交感神经|交感神经]]兴奋，继而引发[[心绞痛|心绞痛]]或[[心肌梗死|心肌梗死]]，故不作为治疗高血压的首选药物。此外，肼屈嗪也引起血浆[[肾素|肾素]]浓度升高，继而引发[[水钠潴留|水钠潴留]]。因此，肼屈嗪常常与[[β-受体阻滞剂|β-受体阻滞剂]]（如：[[普奈洛尔|普奈洛尔]]）和[[利尿剂|利尿剂]]联合应用，用于治疗严重的高血压。

但是，肼屈嗪与[[甲基多巴|甲基多巴]]是治疗[[妊娠期高血压|妊娠期高血压]]的一线药物。<ref name=Bhushan>Bhushan, Vikas, Tao T. Lee, and Ali Ozturk. First Aid for the USMLE Step 1. New York: McGraw-Hill Medical, 2007. 251.</ref>

==副反应==
* [[腹泻|腹泻]]；
* 压力反射所引起的[[心动过速|心动过速]]；
* [[头痛|头痛]]；
* [[食欲|食欲]]减退；
* [[头晕|头晕]]、[[呕吐|呕吐]]；
* [[抑郁|抑郁]]；
* [[心悸|心悸]]；
* [[药物诱发性红斑狼疮|药物诱发性红斑狼疮]]<ref name="pmid17404230">{{cite journal en|author=Mazari L, Ouarzane M, Zouali M |title=Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=104 |issue=15 |pages=6317–22 |pmid=17404230 |pmc=1851062 |doi=10.1073/pnas.0610434104 |url=http://www.pnas.org/cgi/pmidlookup?view=long&pmid=17404230|date=April 2007}}</ref>。

==参考文献==
{{reflist|2}}

{{Nonsympatholytic vasodilatory antihypertensives}}
{{Hydrazines}}

[[Category:抗高血压药物|Category:抗高血压药物]]
[[Category:肝毒素|]]
[[Category:单胺氧化酶抑制剂|Category:单胺氧化酶抑制剂]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]
[[Category:酞嗪|Category:酞嗪]]